These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17407512)

  • 1. Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer.
    Garcia JA; Rosenberg JE; Weinberg V; Scott J; Frohlich M; Park JW; Small EJ
    BJU Int; 2007 Mar; 99(3):519-24. PubMed ID: 17407512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer.
    Gandhok NK; Looney S; Koochekpour S; Sartor O
    Urol Oncol; 2005; 23(3):163-7. PubMed ID: 15907715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
    Semeniuk RC; Venner PM; North S
    Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2009 Mar; 181(3):1091-7. PubMed ID: 19150091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    Int J Urol; 2010 May; 17(5):466-75. PubMed ID: 20337729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer.
    Pfitzenmaier J; Ellis WJ; Hawley S; Arfman EW; Klein JR; Lange PH; Vessella RL
    Urol Oncol; 2007; 25(3):214-20. PubMed ID: 17483018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor cells predict survival in patients with metastatic prostate cancer.
    Moreno JG; Miller MC; Gross S; Allard WJ; Gomella LG; Terstappen LW
    Urology; 2005 Apr; 65(4):713-8. PubMed ID: 15833514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.
    Oefelein MG; Agarwal PK; Resnick MI
    J Urol; 2004 Apr; 171(4):1525-8. PubMed ID: 15017212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma.
    Hotte SJ; Winquist EW; Stitt L; Wilson SM; Chambers AF
    Cancer; 2002 Aug; 95(3):506-12. PubMed ID: 12209742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
    Banu E; Banu A; Medioni J; Levy E; Thiounn N; Mejean A; Andrieu JM; Oudard S
    Prostate; 2007 Oct; 67(14):1543-9. PubMed ID: 17705243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
    Taplin ME; George DJ; Halabi S; Sanford B; Febbo PG; Hennessy KT; Mihos CG; Vogelzang NJ; Small EJ; Kantoff PW
    Urology; 2005 Aug; 66(2):386-91. PubMed ID: 16098367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
    Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
    J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.
    Heng DY; Chi KN
    Can J Urol; 2006 Dec; 13(6):3335-9. PubMed ID: 17187697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
    Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
    Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml.
    Wiebe E; Rodrigues G; Lock M; D'Souza D; Stitt L
    Can J Urol; 2008 Jun; 15(3):4078-83. PubMed ID: 18570713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly specific detection of prostate-specific antigen-positive cells in the blood of patients with prostate cancer or benign prostatic hyperplasia, using a real-time reverse-transcription-polymerase chain reaction method with improved sensitivity.
    Barbero G; Destefanis P; Procida S; Mandili G; Ulliers D; Ceruti C; Fiori C; Maule MM; Fontana D; Giribaldi G; Turrini F
    BJU Int; 2008 Dec; 102(11):1566-72. PubMed ID: 18549428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.